Novel Therapeutic Technology Developed and Manufactured by ADM Tronics for Origin, Inc., Submitted to FDA
October 06 2020 - 11:53AM
InvestorsHub NewsWire
Novel Therapeutic Technology Developed and
Manufactured by ADM Tronics for Origin, Inc., Submitted to FDA for
Investigational Exemption to Conduct Studies on COVID
Patients
Northvale, NJ --
October 6, 2020 -- InvestorsHub NewsWire -- ADM Tronics Unlimited, Inc. (OTCQB:
ADMT) has been advised that Origin, Inc. filed an
Investigational Device Exemption (“IDE”) application with the FDA
to conduct clinical studies to treat patients diagnosed with
COVID-19 with its plasma-generated nitric oxide (“NO”)
technology. ADMT has been developing and has manufactured for
Origin, Inc. the IonoJet™, which allows for targeted delivery of NO
generated by a thermal plasma, produced from room air at the point
of therapy.
Michael Preston, Chairman and President of Origin,
Inc., stated, "Like other nitric oxide companies, we have
recognized the potential ability of NO to stop the replication of
corona viruses. We believe there may be limitations with other
approaches, and we have worked to address these in a novel system
that is designed to allow NO to be administered effectively. ADMT
has been key to our development and will play an important part in
our future.”
In an October 2, 2020 letter to Origin
shareholders, Mr. Preston wrote, “We have today filed an
Investigational Device Exemption (IDE) application with the U.S.
Food and Drug Administration (FDA) under the Compassionate Use
provisions of the Expanded Access pathway for the use of our
plasma-generated nitric oxide (NO) in a physician-sponsored trial
to treat patients diagnosed with
COVID-19.”
“We are so pleased to see Origin’s progress,”
stated Andre DiMino, President of ADMT. “And, we are doubly-pleased
and excited to see that a technology we developed and manufactured
at ADMT for Origin has the potential to help in the battle against
this pandemic.”
Origin, Inc. is a Phase IIb clinical-stage
biotechnology company that applies its proprietary technology to
generate and deliver nitric oxide (NO) from a defined high-energy
plasma stream. Visit
originww.com.
About ADMT
ADMT is a diversified, technology-based developer and manufacturer
of innovative technologies and products. Its core competency
is its ability to conceptualize a technology, bring it through
development, into manufacturing and commercialization, all
in-house. ADMT has three areas of activity: Proprietary
Medical Devices; Medical Device Design, Engineering, Regulatory and
Manufacturing Services; and, Eco-Friendly Formulations from its
headquarters, laboratories, and FDA-Registered medical device
manufacturing operations. ADMT’s multi-disciplinary team of
engineers, researchers, and technologists utilize advanced
technology infrastructure for R&D and commercialization of
diversified technologies. Visit - admtronics.com.
Except for historical information contained herein, the
matters set forth in this news release are “forward-looking”
statements (as defined in the Private Securities Litigation Reform
Act of 1995), including statements regarding future revenue growth
and performance. Although ADMT believes the expectations
reflected in such forward-looking statements are based upon
reasonable assumptions, there can be no assurance that its
expectations will be realized. Forward-looking statements involve
risks and uncertainties that could cause actual results to differ
materially from expectations. Factors that could contribute
to such differences include those described from time to time in
ADMT’s SEC filings, news releases, and other communications. The
Company assumes no obligation to update the information contained
in this news
release.
Andre DiMino
201-767-6040
andre@admtronics.com
Adm Tronics Unlimited (QB) (USOTC:ADMT)
Historical Stock Chart
From Dec 2024 to Jan 2025
Adm Tronics Unlimited (QB) (USOTC:ADMT)
Historical Stock Chart
From Jan 2024 to Jan 2025
